Clinical course, complications, and requirement for advanced therapy in patients with ulcerative colitis
DOI:
https://doi.org/10.22516/25007440.1535Keywords:
Ulcerative colitis, inflammatory bowel diseases, longitudinal studies, biological therapyAbstract
Introduction: Ulcerative colitis is a chronic inflammatory bowel disease whose clinical course and therapeutic requirements have been described mainly in North American and European cohorts. In Latin America, information from real-world longitudinal studies remains limited.
Methodology: Researchers conducted a retrospective case series that included adult patients with a confirmed diagnosis of ulcerative colitis treated at a Colombian referral center between January 2020 and April 2025. They collected sociodemographic variables, disease extent, treatments received, intestinal and extraintestinal complications, surgical requirements, and use of advanced therapies. The analysis was descriptive.
Results: The study included 53 patients, with a predominance of women (60.4%). Proctitis was the most frequent presentation (41.7%). A total of 28.3% experienced at least one intestinal complication, and bleeding requiring hospitalization was the most common (18.9%). Extraintestinal manifestations occurred in 15.1%, while 9.4% required surgical management. A total of 30.2% were refractory to conventional therapy and required escalation to advanced therapies, initiated on average 46 months after diagnosis; vedolizumab was the most frequently used agent.
Conclusions: A significant proportion of patients with ulcerative colitis in this Colombian case series developed complications and required advanced therapies, generally at a late stage. These findings provide local real-world evidence and highlight the need to optimize follow-up and timely therapeutic escalation.
Downloads
References
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756-1770. https://doi.org/10.1016/S0140-6736(16)32126-2
Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms. Dtsch Arztebl Int. 2020;117(33-34):564-574. https://doi.org/10.3238/arztebl.2020.0564
Balderramo D, Quaresma AB, Olivera PA, Savio MC, Villamil MPG, Panaccione R, et al. Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America. Lancet Gastroenterol Hepatol. 2024;9(3):263-272. https://doi.org/10.1016/S2468-1253(23)00284-4
Juliao-Baños F, Kock J, Arrubla M, Calixto O, Camargo J, Cruz L, et al. Trends in the epidemiology of inflammatory bowel disease in Colombia by demographics and region using a nationally representative claims database and characterization of inflammatory bowel disease phenotype in a case series of Colombian patients. Medicine (Baltimore). 2021;100(7):e24729. https://doi.org/10.1097/MD.0000000000024729
Kotze PG, Underwood FE, Damião AOMC, Ferraz JGP, Saad-Hossne R, Toro M, et al. Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review. Clin Gastroenterol Hepatol. 2020;18(2):304-312. https://doi.org/10.1016/j.cgh.2019.06.030
Ciapponi A, Virgilio SA, Berrueta M, Soto NC, Ciganda Á, Rojas Illanes MF, et al. Epidemiology of inflammatory bowel disease in Mexico and Colombia: Analysis of health databases, mathematical modelling and a case-series study. PLoS One. 2020;15(1):e0228256. https://doi.org/10.1371/journal.pone.0228256
Yepes Barreto I, Carmona R, Díaz F, Marín-Jiménez I. Prevalencia y características demográficas de la enfermedad inflamatoria intestinal en Cartagena, Colombia. Rev Colomb Gastroenterol. 2010;25(2):107-111.
Rojas CA, Sánchez-Londoño S, Rojas NE, Sepúlveda M, García J, Jiménez D, et al. Descripción clínico-epidemiológica de pacientes con enfermedad inflamatoria intestinal en una clínica de cuarto nivel en Cali. Rev Colomb Gastroenterol. 2020;35(2):166-173. https://doi.org/10.22516/25007440.409
García-Duperly R, López-Panqueva R, Londoño-Schimmer EE, Rey-Rubiano M, Padrón-Mercado J, Medellín-Abueta A, et al. Características de la enfermedad inflamatoria intestinal con respecto a otros centros nacionales de Colombia. Rev Colomb Gastroenterol. 2022;37(1):48-57. https://doi.org/10.22516/25007440.752
Juliao-Baños F, Puentes F, López R, Saffon MA, Reyes G, Parra V, et al. Characterization of inflammatory bowel disease in Colombia: Results of a national register. Rev Gastroenterol Mex. 2021;86(2):153-162. https://doi.org/10.1016/j.rgmx.2020.05.005.009
Reyes GA, Gil FL, Carvajal GD, Sánchez CB, Aponte DM, Gonzáles CA, et al. Enfermedad inflamatoria intestinal: características de fenotipo y tratamiento en un hospital universitario de Bogotá, Colombia. Rev Colomb Gastroenterol. 2018;33(2):117-126. https://doi.org/10.22516/25007440.196
Selvaratnam S, Gullino S, Shim L, Lee E, Lee A, Paramsothy S, et al. Epidemiology of inflammatory bowel disease in South America: A systematic review. World J Gastroenterol. 2019;25(47):6866-6875. https://doi.org/10.3748/wjg.v25.i47.6866
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Revista colombiana de Gastroenterología

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

| Article metrics | |
|---|---|
| Abstract views | 24 |
| Galley views | 11 |
| PDF Views | 11 |
| HTML views | 0 |
| Other views | 0 |














